Kihealth Europe

The Future of Metabolic Health Begins with Earlier Detection

Kihealth Europe is advancing next-generation diagnostics designed to identify metabolic dysfunction, beta cell stress, and diabetes risk earlier than traditional approaches — enabling preventative intervention and improved outcomes.

Request Investor Information View Market Opportunity
Years-long window where intervention is possible
  1. Healthy Metabolism
    Baseline
  2. Insulin Resistance
    Years before diagnosis
  3. Beta Cell Stress
    Silent progression
  4. Prediabetes
    Often undetected
  5. Type 2 Diabetes
    Clinical diagnosis
Intervention Window
Traditional testing detects disease after irreversible damage. Kihealth aims to measure biology years earlier.

Disease Does Not Begin With Diabetes.
Diabetes Is The Result.

Each step of the funnel represents a population at a different stage of metabolic decline. Hover any stage to see what the metric represents — and why the biology matters before the diagnosis arrives.

Stage 2 of 4
Metabolic Dysfunction
~50% of adults
Show measurable disruption in insulin signaling, lipid handling or beta cell stress — often years before any glucose abnormality.
Kihealth's diagnostics target the upper stages of this funnel — where intervention is still possible and outcomes can still be changed.
Cardiovascular Disease
Kidney Disease
Blindness
Neuropathy
Premature Mortality
€0B+
Annual European economic burden
$0B+
Emerging GLP-1 therapeutic market
0M+
Europeans living with diabetes
0M+
Metabolic dysfunction population

Every Year of Delayed Detection Multiplies the Cost

Cost per patient escalates dramatically along the metabolic disease cascade. Hover or tap each stage to compare.

Stage 1
Healthy Individual
Relative annual cost per patient
€0.5K
Burden index
The later disease is detected, the greater the human and economic burden. The greatest healthcare savings occur before disease becomes irreversible.

Looking Beyond Glucose

Traditional testing measures the consequences of disease. Kihealth measures the biology driving it.

  • Beta Cell Health
    Biology underlying insulin production
  • Metabolic Dysfunction
    Upstream signal before glucose changes
  • Disease Progression
    Longitudinal trajectory tracking
  • Risk Stratification
    Personalized risk identification
  • Therapy Monitoring
    GLP-1 response and adherence
Measures biological changes years earlier in the disease process.
Beta Cell Decline
By diagnosis, function has often declined 80%+.
Healthy0%
Stress0%
Loss0%
Prediabetes0%
Diabetes0%

The future of diagnostics is not measuring disease. The future is measuring risk.

A Multi-Billion Dollar Opportunity

Illustrative addressable markets adjacent to Kihealth's platform — driven by aging populations, GLP-1 adoption, and the shift to prevention. Hover a bar to focus.

Precision Medicine€120B · 11% CAGR
Population Health€90B · 10% CAGR
Employer Wellness€65B · 9% CAGR
Preventative Diagnostics€35B · 12% CAGR
Diabetes Diagnostics€22B · 8% CAGR
Metabolic Health Testing€15B · 14% CAGR
GLP-1 Monitoring€8B · 22% CAGR
Total Addressable
€0B+
Combined illustrative TAM across adjacent metabolic & precision health markets.
Weighted CAGR
0.0%
Average growth across Kihealth-relevant markets through 2030.

One Platform. Multiple Billion-Dollar Stakeholders.

Kihealth sits at the center of the metabolic ecosystem, generating diagnostic intelligence that flows outward to every stakeholder. Hover any node to see the value delivered.

KIHEALTH
PLATFORM
Value Delivered
Patients
Earlier Detection
Years earlier
Risk identified before irreversible damage — opening preventative intervention windows.
1
Of 8
1:N
Platform leverage
∞
Compounding data

Built To Become A Metabolic Intelligence Platform

The long-term opportunity extends far beyond a single diagnostic test. Explore each stage of platform expansion.

Today
BetaIntercept™
Foundational beta cell biology assay measuring metabolic stress upstream of glucose changes.
Stage 1 of 7

Every Test Improves The Platform

A compounding intelligence advantage: the more Kihealth runs, the smarter the platform becomes.

KIHEALTH
  1. 1
    More Patients Tested
  2. 2
    More Biomarker Data
  3. 3
    Better Predictive Models
  4. 4
    Greater Clinical Insights
  5. 5
    More Physician Adoption
  6. 6
    More Strategic Partnerships
Investor takeaway: The platform becomes more valuable as adoption grows.

The Investment Thesis

Diagnostics are becoming foundational infrastructure for precision medicine, preventative healthcare, therapeutic monitoring and population health management.

01
Massive Addressable Market
Metabolic disease is the largest sustained healthcare burden of our generation.
02
Prevention-Focused Shift
Payers, employers and providers are migrating toward earlier, preventative care.
03
Proprietary Diagnostic Platform
Beta cell biology and methylation chemistry unlock earlier biological signal.
04
Multiple Revenue Streams
Clinical testing, pharma partnerships, employer programs, population health.
05
Strategic Pharma Opportunity
Diagnostics align directly with the booming GLP-1 and metabolic therapeutic pipeline.
06
Significant Acquisition Potential
Diagnostics platforms remain among the most strategically acquired healthcare assets.

The Future of Healthcare Is Earlier

Stage 1
Disease Management
Old Healthcare
Stage 2
Disease Prevention
Current Transition
Stage 3
Disease Prediction
Future Healthcare
Destination
KIHEALTH
Diagnostic infrastructure for the future of metabolic health.
Kihealth Europe is building the diagnostic infrastructure for the future of metabolic health. By identifying risk earlier, enabling intervention sooner, and generating actionable clinical intelligence, the platform has the potential to improve outcomes for millions while creating substantial value across the healthcare ecosystem.
Request Investor Information Explore the Science